- Report
- February 2024
- 175 Pages
Global
From €4835EUR$5,000USD£4,144GBP
- Report
- February 2024
- 30 Pages
United States
€2176EUR$2,250USD£1,865GBP
- Report
- March 2024
- 193 Pages
Global
From €3263EUR$3,374USD£2,796GBP
€3625EUR$3,749USD£3,107GBP
- Report
- February 2024
- 250 Pages
Global
From €4835EUR$5,000USD£4,144GBP
- Report
- February 2024
- 175 Pages
Global
From €4835EUR$5,000USD£4,144GBP
- Report
- February 2024
- 120 Pages
Global
From €4594EUR$4,750USD£3,937GBP
- Report
- October 2023
- 180 Pages
Global
From €4739EUR$4,900USD£4,061GBP
- Report
- January 2024
- 113 Pages
Global
From €4352EUR$4,500USD£3,730GBP
- Report
- October 2023
- 85 Pages
United States
From €4594EUR$4,750USD£3,937GBP
- Report
- July 2021
Global
From €918EUR$949USD£787GBP
- Report
- April 2024
Global
From €400EUR$443USD£355GBP
- Report
- October 2022
- 270 Pages
Global
From €3626EUR$3,750USD£3,108GBP
- Report
- August 2022
- 118 Pages
Global
From €4594EUR$4,750USD£3,937GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2659EUR$2,750USD£2,279GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2659EUR$2,750USD£2,279GBP
- Report
- September 2022
- 282 Pages
Global
From €9187EUR$9,500USD£7,874GBP
- Report
- February 2022
- 228 Pages
Global
From €7253EUR$7,500USD£6,216GBP
- Report
- February 2022
- 210 Pages
Global
From €7253EUR$7,500USD£6,216GBP
- Report
- January 2022
- 90 Pages
Global
From €1934EUR$2,000USD£1,658GBP
- Report
- August 2022
- 118 Pages
Global
From €4352EUR$4,500USD£3,730GBP
Humira is a biologic drug used to treat psoriasis, a chronic skin condition. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Humira is the most widely prescribed biologic drug for psoriasis, and is used to treat moderate to severe cases of the condition. It is administered via subcutaneous injection, and is typically used in combination with other treatments such as topical medications and phototherapy.
Humira is a part of a larger market of psoriasis drugs, which includes other biologics such as Enbrel and Remicade, as well as traditional treatments such as topical corticosteroids and vitamin D analogues. The market is highly competitive, with many companies vying for a share of the market.
Some of the companies in the psoriasis drug market include AbbVie, Amgen, Janssen, Novartis, Pfizer, and UCB. Show Less Read more